Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 20, 2019British Journal of Dermatology

Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals

View Full Paper
Ask AI
Bookmark
Share

Authors

JNJenny M. NorlinLeo Pharma (Australia)KNKristoffer NilssonHelsingborgs lasarettUPUlf PerssonSwedish Institute for Health Economics

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Norlin et al. (2019) studied this question.

synapsesocial.com/papers/6a822856eae2581d6f5214dahttps://doi.org/10.1111/bjd.18361
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial2017 · 900 citations
  2. 2Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis2014 · 81 citations
  3. 3Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab2017 · 60 citations
  4. 4PASI 90 response: the new standard in therapeutic efficacy for psoriasis2014 · 194 citations
  5. 5Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort2016 · 50 citations